Page 57 - 22-0424

The International Journal of the Royal Society of Thailand
Volume XI - 2019

Conclusion

Precision medicine has brought significant changes on treatment approach
from the conventional “average patient” norm to a more individualized treatment.
Differences in genomic makeup needs to be taking into consideration to understand

biological and clinical diversity of same diseases. Non-European patients is
under-represented in most cancer genome studies. Dominant presence of one
ancestry may lead to misinterpretation and could cause ineffective treatment in
other ethnic groups as we see in NSCLC, colorectal and breast cancers. Clinical
implementation of cancer precision medicine at the population-level requires
ethnic diversity consideration. However, increasing the participation of the
under-represented population in cancer genomic studies is challenging and
requires a long-term effort. In 2019, the Thai government established the 5-year
Genomics Thailand Initiative, one arm of which is cancer precision medicine with
the aim to collect germline and tumor genome and establish genome databases
on Thai cancer patients (Shotelersuk et al. 2019). Genomic data from cancer
patients in Thailand will be a step towards more accurate diagnostic tests and more
precise treatments to Thai cancer patients and build the foundations for precision
oncology in Southeast Asia region.

References

Ademuyiwa F, Tao Y, Luo J, Weilbaecher K, Ma C. Differences in the mutational
landscape of triple-negative breast cancer in African Americans and
Caucasians. Breast Cancer Res Treat. 2016;161(3):491–499. doi:10.1007/
s10549 -016-4062-y.

Banegas M and Li C. Breast cancer characteristics and outcomes among hispanic
black and hispanic white women. Breast Cancer Res Treat. 2012;134(3):
1297–1304. doi:10.1007/s10549-012-2142-1.

Cancer Genome Atlas Research Network. Comprehensive molecular profiling
of lung adenocarcinoma, Nature. 2014;511:543–550. doi:10.1038/
nature13385.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M et al.
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN
sources and methods. Int J Cancer. 2018;144(8):1941–1953. doi:10.1002/ijc.
31937.

51
Manop Pithukpakorn

11/7/2565 BE 13:27
_22-0424(047-054)6.indd 51
_22-0424(047-054)6.indd 51 11/7/2565 BE 13:27